Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. uri icon

Overview

publication date

  • July 12, 2020

Research

keywords

  • Antineoplastic Agents
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Purines
  • Quinazolinones
  • Transaminases

Identity

PubMed Central ID

  • PMC7829041

Scopus Document Identifier

  • 85087807912

Digital Object Identifier (DOI)

  • 10.1038/s41375-020-0974-y

PubMed ID

  • 32655145

Additional Document Info

volume

  • 34

issue

  • 12